Last week, QLT, a canadian based biotech company focusing on retinal disease, announced the signing of an exclusive agreement option with Mati Therapeutics. QLT ($QLTI) has signed an exclusive option agreement with Mati Therapeutics for its punctal plug delivery system, which delivers drugs to the surface of the eye through the tear film. Mati has the option of up to three 30-Day extensions.
A punctual plug is a small device that is inserted into the tear duct to deliver medication. They are expected to deliver medication for a longer period of time, without as many trips to the doctor's office. If Mati decides to buy the punctal plug assets, it will pay an additional $750,000 on closing as well as certain milestone payments and a low single digit royalty on net sales of products using or developed from the technology. A collaboration also involves taking a risk, so how do you weigh your options? And where do you start?
When it comes to partnerships in Drug Delivery, how you evaluate the pros and cons of each stakeholder, including large multi-national organizations, start-ups, government entities and academic institutions, will directly effect the outcome of your product. To learn more, join us at the 17th Annual Drug Delivery Partnerships, and attend our session: Partnering in 2013 and Beyond: Sustainable Strategies for Growth.
To learn more about the sessions offered at this years event, download our brochure. As a reader of the Drug Delivery Partnerships blog, you get a 15% discount off the standard rate when using code XP1878BLOG to register. We look forward to seeing you February 6-8 in San Diego, CA!
No comments:
Post a Comment